Patient-Derived Tumor Xenografts in Humanized NSG-SGM3 Mice: A New Immuno-Oncology Platform

Time: 9:00 am
day: Day One


  • The addition of 3 human cytokines (GM-CSF, IL-3 & Kit Ligand) into the NSG mouse provides for a more robust myeloid compartment  after humanization
  • Showcase data on the myeloid engraftment kinetics and also show checkpoint inhibitor efficacy against several PDX
  • Leverage humanized mice to assess the risk of immunotherapeutic-associated cytokine release syndrome CRS)